A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261

Gynecologic Oncology

Volumn 127, Issue 1, 2012, Pages 55-62

  Bible, Keith C ^a   Peethambaram, Prema P ^a   Oberg, Ann L ^a   Maples, William ^b   Groteluschen, David L ^c   Boente, Matthew ^d   Burton, Jill K ^a   Gomez Dahl, Leigh C ^a   Tibodeau, Jennifer D ^a   Isham, Crescent R ^a   Maguire, Jacie L ^a   Shridhar, Viji ^a   Kukla, Andrea K ^a   Voll, Kalli J ^a   Mauer, Mathew J ^a   Colevas, Alexander D ^e   Wright, John ^e   Doyle, L Austin ^e   Erlichman, Charles ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c Green Bay Oncology   (United States)

^d Metro Minnesota CCOP   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CDK; Cyclin dependent kinase; Stat 3

Indexed keywords

CISPLATIN; FLAVOPIRIDOL;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EVALUATION; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PERFORMANCE; PERITONEUM CANCER; PERITONEUM CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLAVONOIDS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PIPERIDINES; YOUNG ADULT;

EID: 84865680221     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.05.030     Document Type: Article

References (31)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun Cancer statistics, 2007 CA Cancer J Clin 57 2007 43 66
2. F.M. Muggia Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers Semin Oncol 31 2004 17 24
3. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
4. J. Stebbing, and A. Gaya Pegylated liposomal doxorubicin (Caelyx) in recurrent ovarian cancer Cancer Treat Rev 28 2002 121 125
5. T.J. Herzog Clinical experience with topotecan in relapsed ovarian cancer Gynecol Oncol 90 2003 S3 S7
6. G. D'Agostino, J. del Campo, B. Mellado, M.A. Izquierdo, T. Minarik, and L. Cirri A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer Int J Gynecol Cancer 16 2006 71 76
7. M.V. Seiden, A.N. Gordon, D.C. Bodurka, U.A. Matulonia, R.T. Person, and E. Reed 3rd A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer Gynecol Oncol 101 2006 55 61
8. M.V. Seiden, H.A. Burris, U. Matulonis, J.B. Hall, D.K. Armstrong, and J. Speyer A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies Gynecol Oncol 104 2007 727 731
9. U. Wagner, A. du Bois, J. Pfisterer, J. Huober, S. Loibl, and H.J. Lück Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6) Gynecol Oncol 105 2007 132 137
10. D.S. Alberts, P.Y. Liu, S.P. Wilczynski, A. Jang, J. Moon, and J.H. Ward Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211) Int J Gynecol Cancer 17 2007 784 788
11. R.L. Coleman, R.R. Broaddus, D.C. Bodurka, J.K. Wolf, T.W. Burke, and J.J. Kavanagh Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers Gynecol Oncol 101 2006 126 131
12. M. Markman, K. Webster, K. Zanotti, G. Peterson, B. Kulp, and J. Belinson Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials Gynecol Oncol 93 2004 699 701
13. K.C. Bible, R.H. Bible Jr., T.J. Kottke, P.A. Svingen, K. Xu, and Y.P. Pang Flavopiridol binds to Duplex DNA Cancer Res 60 2000 2419 2428
14. Y.K. Lee, C.R. Isham, S.H. Kaufmann, and K.C. Bible Flavopiridol Disrupts STAT3/DNA Interactions, Attenuates STAT3-directed Transcription and Combines with the Jak Kinase Inhibitor AG490 to Achieve Cytotoxic Synergy Mol Cancer Ther 5 2006 138 148
15. K.C. Bible, and S.H. Kaufmann Flavopiridol (NSC 649890, L86-8275): A cytotoxic flavone that induces death in non-cycling A549 human lung carcinoma cells Cancer Res 56 1996 4856 4861
16. K.C. Bible, S.A. Boerner, K. Kirkland, K.L. Anderl, D. Bartlet Jr., and P.A. Svingen Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol Clin Cancer Res 6 2000 661 670
17. K.C. Bible, J.L. Lensing, S.A. Nelson, Y.K. Lee, J.M. Reid, and M.M. Ames A phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic endpoints Clin Cancer Res 11 2005 5935 5941
18. K.C. Bible, and S.H. Kaufmann Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration Cancer Res 57 1997 3375 3380
19. T.C. Chou, and P. Talalay Analyses of combined drug effects: a new look at a very old problem Trends Pharmacol Sci 4 1983 450 454
20. W.R. Greco, G. Bravo, and J.C. Parsons The search for synergy: a critical review from a response surface perspective Pharmacol Rev 47 1995 331 385
21. J.J. Lee, M. Kong, G.D. Ayers, and R. Lotan Interaction Index and Different Methods For Determining Drug Interaction In Combination Therapy J Biopharm Stat 17 2007 461 480
22. D.M. Nelson, B. Joseph, J. Hillion, J. Segal, J.E. Karp, and L.M. Resar Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia Leuk Lymphoma 52 2011 1999 2006
23. T. Ohta, A. Khurana, J. Maguire, X. He, J. Chien, and K. Bible Flavopiridol-induced upregulation of HtrA1 is associated with suppression of its negative transcriptional regulator WT-1 and with enhanced chemosensitivity [abstract] Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6 2011 AACR Orlando, Florida: Philadelphia (PA) Abstract 4015
24. S.L. Hillman, S.J. Mandrekar, B. Bot, R.P. DeMatteo, E.A. Perez, and K.V. Ballman Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation J Clin Oncol 28 2010 3002 3007
25. K. Ushijima Treatment for recurrent ovarian cancer-at first relapse J Oncol 2010 2010 497429
26. G.B. Ojeda, M.A. Gonzalez, B.I. Bover, M.X. Fabugati, B. Mellado, and M.J. Rubio Perez A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial Am J Clin Oncol 31 2008 481 487
27. D.S. Miller, J.A. Blessing, C.N. Krasner, R.S. Mannel, P. Hanjani, and M.L. Pearl Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group J Clin Oncol 27 2009 2686 2691
28. S. Makhija, L.C. Amler, D. Glenn, F.R. Ueland, M.A. Gold, and D.S. Dizon Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer J Clin Oncol 28 2010 1215 1223
29. R. Sharma, J. Graham, H. Mitchell, A. Brooks, S. Blagden, and H. Gabra Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer Br J Cancer 100 2009 707 712
30. K. De Geest, J.A. Blessing, R.T. Morris, S.D. Yamada, B.J. Monk, and S.L. Zweizig Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 28 2010 149 153
31. S.K. Chambers, M.C. Clouser, A.F. Baker, D.J. Roe, H. Cui, and M.A. Brewer Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer Clin Cancer Res 16 2010 5320 5328